V. Serra

Interpretable Inflammation Landscape of Circulating Immune cells

P. Vandergheynst, A. Villani, M. Nawijn, 2023, bioRxiv.

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

T. Aas, P. Lønning, S. Knappskog, 2023, JCO precision oncology.

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.

R. D. de Bruin, D. Carbone, S. Wander, 2024, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer

S. Sdelci, Anestis Gkanogiannis, Chiara Cannatá, 2023, EMBO molecular medicine.

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer.

J. Balmaña, J. Frankum, A. Llop-Guevara, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

R. Dienstmann, O. Díez, S. Gutiérrez‐Enríquez, 2024, Genome medicine.